Residual Curarization and Its Incidence at Tracheal Extubation in China
Launched by XINMIN WU · Jun 5, 2013
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective, multi-site, anesthesiologist and PACU nurse TOF-Watch SX® blinded observational study of surgical patients undergoing elective laparoscopic or open abdominal procedures requiring general anesthesia and non-depolarizing neuromuscular blockade. There are two temporal aspects to the data collection: a prospective data collection in the OR and PACU; and a retrospective chart review one week after hospital discharge.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age≥18;
- • American Society of Anesthesiologists(ASA) class 1-3;
- • Scheduled for elective open or laparoscopic abdominal surgery that is anticipated to last less than 4 hours;
- • Administration of general anesthesia and ≥ 1 dose of non-depolarizing neuromuscular blockers for endotracheal intubation or maintenance of neuromuscular blockade;
- • Planned for extubation to occur in the OR;
- • Signed informed consent.
- Exclusion Criteria:
- • Redo surgery on the same hospital admission;
- • Pre-established need or expected to require post-operative mechanical ventilation;
- • Conditions, surgical procedures, or participant positioning that may interfere with TOF-Watch SX® operation, calibration, or accuracy;
- • Anesthesiologist use of objective neuromuscular monitoring during surgery (e.g. mechanomyography, electromyography or related method);
- • Pregnancy;
- • Participation in any other clinical trial;
- • Member or a family member of the personnel of the investigational or Sponsor staff directly involved with this trial.
About Xinmin Wu
Xinmin Wu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutics and enhancing patient care, Xinmin Wu actively collaborates with healthcare professionals, research institutions, and regulatory bodies to design and implement robust clinical trials. The organization prioritizes ethical standards, patient safety, and scientific integrity, ensuring that all studies are conducted with the utmost diligence and transparency. Through its comprehensive approach, Xinmin Wu aims to contribute significantly to the improvement of health outcomes and the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, , China
Hangzhou, Zhejiang, China
Beijing, , China
Chengdu, Sichuan, China
Beijing, , China
Shanghai, , China
Shenyang, Liaoning, China
Beijing, , China
Wuhan, Hubei, China
Shanghai, , China
Beijing, , China
Jinan, Shandong, China
Shanghai, , China
Guangzhou, Guangdong, China
Wuhan, Hubei, China
Zhengzhou, Henan, China
Guangzhou, Guangdong, China
Changsha, Hunan, China
Guangzhou, Guangdong, China
Nanjing, Jiangsu, China
Yangzhou, Jiangsu, China
Changchun, Jilin, China
Xi'an, Shanxi, China
Urumqi, Xinjiang, China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Wenzhou, Zhejiang, China
Chongqing, , China
Shanghai, , China
Shanghai, , China
Patients applied
Trial Officials
Xinmin Wu, MD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials